Sun Pharmaceutical Obtains FDA Approval for Generic Blood Cancer Drug
The FDA announced on Friday the approval for a generic copy of the drug Gleevec for the treatment of myeloid leukemia, a rare form of blood cancer. The drug was developed by the Indian company Sun Pharmaceutical and will be permitted to launch on Feburary 1st, 2016. The approval marks the 18th drug approved for cancer care in 2015.
The original developer of Gleevec, Novartis, has reported annual sales for its drug of over $2.5 billion in the United States alone. However, those sales will now certainly take a hit with a cheaper alternative now available for patients.